Log In
Print
BCIQ
Print
Print this Print this
 

lampalizumab (RG7417)

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionHumanized mAb fragment targeting complement factor D (CFD)
Molecular Target Complement factor D (CFD)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat geographic atrophy (GA) associated with age-related macular degeneration (AMD)
Regulatory Designation

Partner

Genentech Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today